Newest
PEBO ▼ sold $76K · Augenstein Mark filed 1d agoBBT ▲ bought $105K · Hollister Thomas J filed 2d agoBBT ▼ sold $20K · Eagan John Buckley filed 2d agoGS ▼ sold $60K · LESLIE ERICKA T filed 2d agoGS ▼ sold $163K · LESLIE ERICKA T filed 2d agoMSCI ▼ sold $1.5M · Gutowski Robert J. filed 2d agoGL ▼ sold $2.2M · MAJORS MICHAEL CLAY filed 2d agoPHR ▲ bought $362 · Linetsky David filed 2d agoPHR ▲ bought $320 · Linetsky David filed 2d agoRVI ▲ bought $23K · Whitney Meredith filed 2d agoLEO ▲ bought $369K · Saba Capital Management, L.P. filed 2d agoPG ▼ sold $5.7M · Jejurikar Shailesh filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoICLR ▼ sold $15K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoPG ▼ sold $698K · Gama Paul filed 2d ago

Insider / Xilio Therapeutics, Inc.

Russo Rene

PRESIDENT AND CEO at Xilio Therapeutics, Inc.

Company
Xilio Therapeutics, Inc.
Ticker
XLO
First filing on record
November 25, 2025
Latest trade on record
January 1, 2026
SEC filings
EDGAR ↗

Russo Rene, PRESIDENT AND CEO at Xilio Therapeutics, Inc., has disclosed 20 transactions in XLO since November 25, 2025: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed January 5, 2026, 4 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.

Last updated January 5, 2026 · Source: SEC EDGAR Form 4 filings

Transactions
20
Open-market buys
0
Sales
0
Avg. disclosure lag
4.0d

Trading in charts

Trade timeline

When does this person trade, how big, and in which direction? Every trade in the last 12 months.

Bought (above the line)Sold (below the line)Other transaction
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep

In the last 12 months Russo Rene reported 20 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.

Reporting lag

Does this person report on time? One bar per filing against the Form 4 deadline.

On timeLate
Form 4 deadlineoldest filingnewest

1 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).

What kind of transactions

Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.

Rows by Form 4 transaction code
CodeMeaningRowsSharesValue
AGrant or award105,773,470—
DSale back to the company82,198,212—
MOption exercise or conversion288,500—
Rows by year of the trade
YearRowsBoughtSold
2026200
20251800

Transactions

Download XLO trades (CSV)79 rows · 27 KB · every filer in this ticker, this insider included · all downloads

SecuritySideTrade dateDisclosedLagSharesPriceValueFlagsSourceShare
XLOOption / conversion MJanuary 1, 2026January 5, 20264d44,250——derivativeForm 4 ↗
XLOOther ADecember 31, 2025January 5, 20265d1,500,258——latederivativeForm 4 ↗
XLOOption / conversion MJanuary 1, 2026January 5, 20264d44,250——Form 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d700,000——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d700,000——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d350,000——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d350,000——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d150,000——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d150,000——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d100,000——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d100,000——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d50,041——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d50,041——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d135,134——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d135,134——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d473,334——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d473,334——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d239,703——derivativeForm 4 ↗
XLOOption / conversion DNovember 21, 2025November 25, 20254d239,703——derivativeForm 4 ↗
XLOOther ANovember 21, 2025November 25, 20254d2,075,000——derivativeForm 4 ↗

Filings

FiledFormAccessionRowsStatusSource
January 5, 2026Form 40001193125-26-0025123publishedEDGAR ↗
November 25, 2025Form 40001193125-25-29720317publishedEDGAR ↗

Other insiders at Xilio Therapeutics, Inc.

Everyone on file, with contracts and lobbying under the company's name: Xilio Therapeutics, Inc..

Guides for this page

Sources and method

Official sources behind this page
SourceFilingsRowsFirst filedNewest filedRead the originals
SEC EDGAR, Form 4220November 25, 2025January 5, 2026Form 4 list on EDGAR

Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.

Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.

Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.